Design Therapeutics, Inc. 8-K

What Happened
Design Therapeutics, Inc. (DSGN) announced on March 31, 2026 that its Board appointed David Shapiro, M.D., as a Class III director, effective immediately. Dr. Shapiro’s term runs through the company’s 2027 annual meeting of stockholders. He was also named to the Board’s Nominating and Corporate Governance Committee.

Key Details

• Appointment date: March 31, 2026; term ends at the 2027 annual meeting.
• Committee assignment: Member of the Nominating and Corporate Governance Committee.
• Cash compensation: Under the company’s non-employee director policy, Dr. Shapiro will receive $40,000 annually for Board service and $5,000 annually for Nominating Committee service.
• Equity awards: Initial option to purchase 60,000 shares vesting monthly over three years, plus a prorated annual option for 7,500 shares vesting monthly over one year.
• Governance paperwork: Dr. Shapiro and the company entered the standard directors/officers indemnification agreement referenced in the company’s Form 10-K filed March 9, 2026 (Exhibit 10.1).

Why It Matters
This filing notifies investors of a governance change—addition of a new independent director and a committee assignment—which may influence board composition and oversight. The disclosed cash retainer and stock option grants are standard non-employee director compensation; the equity awards will vest over time and be recorded as compensation expense per accounting rules.